DEVELOPMENTS IN FIBRINOLYTIC THERAPY FOR THROMBO-EMBOLIC DISEASE
Authors: S SHERRY, A P FLETCHER, N ALKJAERSIG
Journal: Annals of Internal Medicine (1959)

Article1 March 1959DEVELOPMENTS IN FIBRINOLYTIC THERAPY FOR THROMBO-EMBOLIC DISEASESOL SHERRY, M.D., ANTHONY P. FLETCHER, M.D., NORMA ALKJAERSIG, M.S.SOL SHERRY, M.D., ANTHONY P. FLETCHER, M.D., NORMA ALKJAERSIG, M.S.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-50-3-560 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIntravascular thrombi in animals may be dissolved by activating the naturally occurring fibrinolytic enzyme system.1, 2In figure 1 (on the left), there is illustrated an experimental thrombus in the femoral artery of a dog five days after its production. The artery is cut in a semilongitudinal fashion, and evidence of early organization of the well formed thrombus is apparent. The section of artery shown on the right in figure 1 was taken from a second streptokinase-treated animal in which an experimental thrombus had been produced. Both specimens were taken after the same interval. The lumen is patent in this...Bibliography1. JohnsonTillett AJWS: The lysis in rabbits of intravascular blood clots by the streptococcal fibrinolytic system (streptokinase), J. Exper. Med. 95: 449, 1952. CrossrefMedlineGoogle Scholar2. SherryTitchenerGottesmanWassermanTroll SALPW: The enzymatic dissolution of experimental arterial thrombi in the dog by trypsin, chymotrypsin, and plasminogen activators, J. Clin. Investigation 33: 1303, 1954. CrossrefMedlineGoogle Scholar3. TillettJohnsonMcCarty WSAJWR: The intravenous infusion of the streptococcal fibrinolytic principle (streptokinase) into patients, J. Clin. Investigation, 34: 169, 1955. CrossrefMedlineGoogle Scholar4. Cliffton EE: The use of plasmin in humans, Ann. New York Acad. Sc. 68: 209, 1957. CrossrefMedlineGoogle Scholar5. AmbrusAmbrusBackSokalCollins JLCMNJEGL: Clinical and experimental studies on fibrinolytic enzymes, Ann. New York Acad. Sc. 68: 97, 1957. CrossrefMedlineGoogle Scholar6. Von Kaulla KN: Intravenous protein-free pyrogen; a powerful fibrinolytic agent in man, Circulation 17: 187, 1958. CrossrefMedlineGoogle Scholar7. SherryFletcherAlkjaersigSmyrniotis SAPNFE: An approach to intravascular fibrinolysis in man, Tr. A. Am. Physicians 70: 288, 1957. MedlineGoogle Scholar8. SherryCallawayFreiberg SDWR: Prevention of postoperative adhesions in the dog by intravenous injections of plasminogen activators, Proc. Soc. Exper. Biol. and Med. 90: 1, 1955. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: St. Louis, Missouri*Received for publication May 12, 1958.Presented as a Morning Lecture at the Thirty-ninth Annual Session of The American College of Physicians, Atlantic City, New Jersey, April 29, 1958.From the Research Institute, The Jewish Hospital of St. Louis, and the Department of Medicine, Washington University School of Medicine, St. Louis.†Supported by grants from the National Heart Institute, National Institutes of Health, and Lederle Laboratories Division, American Cyanamid Company.Requests for reprints should be addressed to Sol Sherry, M.D., Washington University School of Medicine, 600 South Kingshighway, St. Louis 10, Missouri. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByThrombolysis and Reocclusion in Experimental Jugular Vein and Coronary Artery ThrombosisAnticoagulants, Antithrombotic and Thrombolytic AgentsInhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis.Plasmin inhibitors in the prevention of systemic effects during thrombolytic therapy: Specific role of the plasminogen-binding form of α2-antiplasminComparison of thrombolytic agents: Selected hematologic, vascular and clinical eventsThrombolytic Therapy: Current StatusThrombolytic Agents for Acute Myocardial InfarctionThe swollen legFibrinolysis: An Unusual Cause of BleedingFibrinolytic Disorders in ObstetricsSind in vitro-Thrombolyseversuche auf intravitale Verhältnisse zu übertragen?Zum Mechanismus der Fibrinolyse durch StreptokinaseThe Problem of Frostbite in Civilian Medical PracticeFibrinolytic mechanisms and the development of thrombolytic therapyOn the Mechanism of Thrombolysis by PlasminFibrinolytic AgentsLyse von humanen Blutgerinnseln im ReagenzglasFibrinolysisAntibodies after Streptokinase Treatment, and their Importance for Repeated Fibrinolytic TherapyClinical pharmacology of various types of fibrinolytic enzyme preparationsDose response curves with varying doses of fibrinolysin∗A Deficiency of Pulmonary Fibrinolysis in Hyaline-Membrane DiseaseUse of anticoagulant and fibrinolytic agentsFibrinolysin (Plasmin) Therapy in Acute Deep Thrombophlebitis 1 March 1959Volume 50, Issue 3Page: 560-570KeywordsArteriesBlood plasmaEnzymesFemoral arteriesFibrinolysisHeartHospital medicineInformation technologyThrombosis Issue Published: 1 March 1959 PDF DownloadLoading ...